Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
about
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
description
scientific article published on 06 June 2019
@en
name
Multiomics Profiling Establish ...... Differential Clinical Activity
@en
type
label
Multiomics Profiling Establish ...... Differential Clinical Activity
@en
prefLabel
Multiomics Profiling Establish ...... Differential Clinical Activity
@en
P2093
P1476
Multiomics Profiling Establish ...... Differential Clinical Activity
@en
P2093
Caitlin E Mills
Changchang Liu
Charlotte S Walmsley
Dejan Juric
Kartik Subramanian
Mirra Chung
Robert A Everley
Sarah A Boswell
P304
1067-1080.e8
P356
10.1016/J.CHEMBIOL.2019.05.005
P577
2019-06-06T00:00:00Z